Reata Pharmaceuticals, Inc. announced that Martin W. Edwards, M.D., William D. McClellan, Jr. and R. Kent McGaughy Jr., resigned as a director of the Company. Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company. The resignations of such directors at and immediately following the Effective Time did not result from any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.

At the Effective Time, each of Fearghas Carruthers, Michael Dambach and Robin Kramer became a director of Reata. Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata. In accordance with the terms of the Merger Agreement, individuals designated by Biogen were elected as officers of Reata, effective as of immediately following the Effective Time.